138608-95-4

Basic information

• Product Name: 5-Pyrimidinecarbonitrile, 1,4-dihydro-6-(4-methoxyphenyl)-4-oxo-2-[(phenylmethyl)thio]-
• CAS NO: 138608-95-4
• Molecular Formula: C19H15N3O2S
• Molecular Weight: 349.413
• Mol File: 138608-95-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-Pyrimidinecarbonitrile, 1,4-dihydro-6-(4-methoxyphenyl)-4-oxo-2-[(phenylmethyl)thio]-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinecarbonitrile, 1,4-dihydro-6-(4-methoxyphenyl)-4-oxo-2-[(phenylmethyl)thio]-(138608-95-4)
• EPA Substance Registry System: 5-Pyrimidinecarbonitrile, 1,4-dihydro-6-(4-methoxyphenyl)-4-oxo-2-[(phenylmethyl)thio]-(138608-95-4)

Safety Data

• Hazardous Substances Data: 138608-95-4(Hazardous Substances Data)

Upstream product

• 70638-54-9 5-cyano-4-oxo-6-(4-methoxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine 
• 123-11-5 4-methoxy-benzaldehyde 
• 538-28-3 S-benzylisothiourea hydrochloride 
• 105-56-6 ethyl 2-cyanoacetate 
• 100-39-0 benzyl bromide 

Downstream Products

• 1425974-30-6 C₂₀H₁₇N₃O₂S 
• 1425974-24-8 C₂₁H₁₉N₃O₂S 
• 1425974-28-2 C₂₁H₁₉N₃O₂S 
• 1425974-07-7 C₂₃H₂₂N₄O₂S 
• 1425974-10-2 C₃₁H₃₀N₄OS 
• 1425974-12-4 C₃₁H₂₈N₄O₂S 
• 1425974-04-4 C₂₄H₂₀N₄OS₂ 
• 1425974-05-5 C₂₆H₂₂N₄OS 
• 1425974-06-6 C₂₇H₂₄N₄OS 
• 1425974-08-8 C₂₃H₂₂N₄OS₂ 
• 1425974-09-9 C₂₅H₂₆N₄OS 
• 1425974-13-5 C₃₀H₂₈N₄OS 

Relevant articles and documents

Synthesis of a 2,4,6-trisubstituted 5-cyano-pyrimidine library and evaluation of its immunosuppressive activity in a Mixed Lymphocyte Reaction assay

A series of novel pyrimidine analogues were synthesized and evaluated for immunosuppressive activity in the Mixed Lymphocyte Reaction assay, which is well-known as the in vitro model for in vivo rejection after organ transplantation. Systematic variation of the substituents at positions 2, 4 and 6 of the pyrimidine scaffold led to the discovery of 2-benzylthio-5-cyano-6-(4- methoxyphenyl)-4-morpholinopyrimidine with an IC50 value of 1.6 μM in the MLR assay.

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease

A series of 2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidine as SARS-CoV 3CL protease inhibitors were developed and their potency was evaluated by in vitro protease inhibitory assays. Two candidates had encouraging results for the development of new anti-SARS compounds.